Cardiac contrast agent and preparation method thereof

Through nano-scale liposome encapsulation and targeting polypeptide-modified iodine-based complexes, the problems of unsatisfactory distribution of traditional cardiac contrast agents are solved, and clearer and more accurate cardiography and reduced side effects are achieved.

CN118949080APending Publication Date: 2024-11-15SHANGLUO TRADITIONAL CHINESE MEDICINE HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411026078.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The distribution and metabolic properties of traditional cardiac contrast agents in the body are not ideal, resulting in the inconsistency effect being unclear and accurate enough, and may accumulate in non-cardiac tissues, increasing the risk of side effects and adverse reactions, affecting diagnostic accuracy, and structural instability and iodine. The binding inhomogeneity of organic ligands reduces imaging quality.

Method used

Using nano-scale liposome-encapsulated iodine-based complexes and modifying specific peptides targeting heart cells on their surfaces, forming stable iodine-based complexes through coordination reactions, controlling pH values ​​and adding stabilizers to ensure iodine atoms Effective binding and uniform distribution with organic ligands.

Benefits of technology

It improves the distribution and metabolic properties of cardiac contrast agents in the body, enhances the permeability in cardiac tissues, improves the accuracy and specificity of imaging, reduces the impact on non-target areas, and reduces side effects and potential toxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118949080A_ABST
    Figure CN118949080A_ABST
Patent Text Reader

Abstract

The invention discloses a cardiac contrast agent and a preparation method thereof, and relates to the technical field of contrast agent preparation, basic materials for preparation of the cardiac contrast agent comprise an iodine-based compound, a stabilizer, a pH regulator and an organic solution, the iodine-based compound is a compound wrapped by nanoscale liposome, and the stabilizer is a compound wrapped by nanoscale liposome. The iodine-based compound is formed by combining iodine atoms and organic ligands through coordinate bonds, and the surface of the liposome is modified with specific polypeptide targeting cardiac cells. The liposome has the advantages that the iodine-based compound is wrapped by the nano-scale liposome, so that the distribution and metabolism characteristics of a cardiac contrast agent in a body can be improved, and the targeting cardiac contrast agent has a good application prospect. According to the present invention, the nano-scale liposome surface is modified with the specific polypeptide targeting the cardiac cells, such that the cardiac contrast agent can accurately act on the cardiac tissue, and the imaging accuracy and the imaging specificity can be improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of contrast agent preparation, in particular to a cardiac contrast agent and a preparation method thereof. Background Art

[0002] Contrast media (also known as contrast media) are chemicals injected (or taken) into human tissues or organs to enhance the effect of image observation. The density of these products is higher or lower than that of the surrounding tissues, and the contrast formed is used to display images with certain instruments;

[0003] In angiography, when a large dose of contrast medium is injected, there are many factors that affect its toxicity. In cardiovascular angiography, the risk of poisoning increases several times when injected quickly than when injected slowly. This is mainly due to the hyperosmotic effect of the contrast medium. Even newer preparations have some chemical toxicity. Under certain circumstances, the tolerance of the myocardium, brain, spinal cord or kidney is reduced. Regarding the choice of contrast medium, meglumine salt is the best choice for cerebral angiography, while sodium salt and meglumine salt mixture is used for cardiac angiography. Allergic reactions are less common in angiography than in urinary tract angiography, which may be because the contrast medium does not pass directly through the lungs during angiography.

[0004] Heart disease has always been a major problem threatening human health. Accurate diagnosis is crucial for the treatment and prognosis of heart disease. As an important diagnostic technique, cardiac angiography is based on the use of effective contrast agents to clearly display the structure and function of heart vessels and tissues.

[0005] Traditional cardiac contrast agents have some limitations in their application. For example, their distribution and metabolic characteristics in the body are not ideal, which may lead to unclear and inaccurate contrast effects, affecting the accurate diagnosis of heart disease. At the same time, due to the lack of specific targeting, these contrast agents may also accumulate in non-cardiac tissues to a certain extent, which not only increases the risk of side effects and adverse reactions, but also may interfere with the accurate observation of the heart. In addition, the stability and structural uniformity of the contrast agent will also affect its imaging effect. The unstable structure may change in the body, resulting in a decrease in imaging quality. Moreover, if the combination of iodine and organic ligands is not effective and uniform, the contrast agent will be unevenly distributed in the body, further reducing the accuracy of diagnosis. The residues of unreacted iodine and organic ligands in the human body may also bring potential toxicity and have adverse effects on the patient's health. To this end, we propose a cardiac contrast agent and a preparation method thereof. Summary of the invention

[0006] The object of the present invention is to provide a cardiac contrast agent and a preparation method thereof.

[0007] In order to solve the problems raised in the above background technology, the present invention provides the following technical solutions: a method for preparing a cardiac contrast agent, wherein the basic materials used for preparing the cardiac contrast agent are an iodine-based complex, a stabilizer, a pH regulator and an organic solution, wherein the iodine-based complex is a complex encapsulated by nano-liposomes, wherein the iodine-based complex is formed by combining iodine atoms and organic ligands through coordination bonds, and the surface of the liposomes is modified with a specific polypeptide targeting cardiac cells, and the specific steps of the method for preparing the cardiac contrast agent are as follows:

[0008] Step 1, preparing an iodine-based complex, coordinating the lone pair of electrons in the organic ligand with the empty orbital of the iodine atom, wherein the organic ligand contains nitrogen, oxygen and sulfur atoms, adding iodine and the organic ligand into a sealed stirring tank for mixing, adding an inert gas into the sealed stirring tank during the reaction, stirring the reaction at 45° C., and adding a pH adjuster to adjust the pH value of the mixed solution to obtain an iodine-based complex mixed solution;

[0009] Step 2, preparing an iodine-based complex encapsulated in nano-liposomes, dissolving a lipid material in an organic solution to prepare a lipid solution, dropping the iodine-based complex mixed solution into the lipid solution, stirring until the iodine-based complex mixed solution is completely dissolved, preparing a mixed base material, and then transferring the mixed base material to a rotary evaporator, removing the organic solvent under vacuum conditions to form a uniform lipid film, adding a stabilizer thereto, hydrating for 1 hour, and then ultrasonically treating the film to prepare a crude iodine-based complex suspension encapsulated in liposomes, filtering the suspension through a nano-scale filter, and preparing an iodine-based complex encapsulated in nano-liposomes with uniform particle size;

[0010] Step 3: modifying the surface of the nano-liposome with a specific peptide targeting cardiac cells, introducing active groups on the surface of the nano-liposome using a chemical coupling method, and connecting the specific peptide to the active group using a chemical reaction to obtain an iodine-based complex encapsulated by the nano-liposome modified with the specific peptide;

[0011] Step 4: Performing quality inspection on the iodine-based complex encapsulated by the nano-liposome modified with the specific peptide, including its physical properties, chemical properties and stability under different states, and performing biocompatibility testing and imaging effect evaluation;

[0012] Step 5: sterilize the iodine-based complex encapsulated by the nano-liposome modified with the specific polypeptide that has passed the test, and put it into a sterile glass syringe that meets medical standards and store it at 2°C-8°C.

[0013] As a further solution of the present invention: in step 1, the organic ligand is a nitrogen-containing heterocyclic compound, and during the stirring of iodine and the organic ligand, a pH adjuster is added according to the pH value of the reaction system to adjust the pH value of the finally obtained iodine-based complex mixed solution to between 7.35 and 7.45.

[0014] As a further solution of the present invention: the pH values ​​of all materials prepared in steps 1 to 5 need to be controlled between 7.25 and 7.45.

[0015] As a further solution of the present invention: in step 2, the stabilizer is ethylenediaminetetraacetic acid, and the main components of the lipid solution are phospholipids and cholesterol, and the mass ratio thereof is 1:1.

[0016] As a further solution of the present invention: in the step 2, the ultrasonic frequency is 20kHz-80kHz, the ultrasonic time is 15min-20min, and the pore size of the nano-filter is 200nm-300nm.

[0017] As a further solution of the present invention: in the step three, before modifying the surface of the nano-liposome with a specific polypeptide targeting cardiac cells, the active groups on the surface need to be activated, and the activator is 1-ethyl-3-carbodiimide.

[0018] As a further solution of the present invention: in step 3, the specific operation method is as follows:

[0019] The prepared nano-scale liposomes are subjected to ultrafiltration to remove impurities, and the pH value thereof is adjusted to between 7.35 and 7.45. The liposomes are treated with a chemical reagent, dithiothreitol, to expose thiol groups on the surface of the liposomes for reaction, and the specific polypeptide is chemically modified to introduce a maleimide group at one end thereof. After the modification, the polypeptide solution is mixed with the pretreated liposome solution, and after slow stirring, the mixture is placed in an oxygen-free, light-proof environment at a temperature of 4°C to 10°C for natural reaction for 2h to 4h. After the reaction is completed, glutathione is added to terminate the reaction, and the product is purified by gel filtration chromatography to obtain an iodine-based complex encapsulated by nano-scale liposomes modified with the specific polypeptide.

[0020] As a further scheme of the present invention: in the step four, the physical properties include particle size distribution, potential measurement and morphological observation, the chemical properties include iodine content measurement and organic ligand binding ratio, the stability under different states includes thermal stability, acid-base stability and long-term storage stability, the biocompatibility includes cytotoxicity test and in vivo metabolic distribution, and the imaging effect evaluation includes in vitro simulation of the cardiac environment.

[0021] In addition, the present invention also provides a cardiac contrast agent, which is prepared by encapsulating an iodine-based complex with nano-liposomes and then modifying the surface of the complex with a specific polypeptide.

[0022] By adopting the above technical solution, compared with the prior art, the beneficial effects of the present invention are:

[0023] 1. The present invention can help improve the distribution and metabolic characteristics of cardiac contrast agents in the body by encapsulating iodine-based complexes with nano-sized liposomes, and enhance their penetration into cardiac tissues, making cardiac imaging clearer. By modifying the surface of nano-sized liposomes with specific peptides targeting cardiac cells, cardiac contrast agents can act more accurately on cardiac tissues, improve the accuracy and specificity of imaging, and reduce the impact on other non-target areas, thereby reducing the side effects and adverse reactions of using the cardiac contrast agents.

[0024] 2. The present invention helps to form a structurally stable iodine-based complex by stirring and mixing iodine and organic ligands, thereby maintaining the stability of its contrast performance in actual use and reducing the problem of poor imaging effect due to structural changes. Reasonable coordination reaction can ensure the effectiveness and uniformity of the combination of iodine atoms and organic ligands, so that the contrast agent can be more evenly distributed in the body. At the same time, it can reduce the residue of unreacted iodine and organic ligands in the human body, effectively reducing the adverse effects of potential toxicity on the human body. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 This is a schematic diagram of the contrast agent preparation process in an embodiment of the present invention;

[0026] Figure 2 Schematic diagram of the comparison of contrast agent particle sizes in an embodiment of the present invention;

[0027] Figure 3 Schematic diagram for comparing contrast agent characteristics in embodiments of the present invention. DETAILED DESCRIPTION

[0028] The specific embodiments of the present invention are further described below in conjunction with the accompanying drawings. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in the various embodiments of the present invention described below can be combined with each other as long as they do not conflict with each other.

[0029] As attached Figure 1 -Attached Figure 3As shown, the present invention provides a method for preparing a cardiac contrast agent. The basic materials used for preparing the cardiac contrast agent are an iodine-based complex, a stabilizer, a pH regulator, and an organic solution. The iodine-based complex is a complex encapsulated by nano-liposomes. The iodine-based complex is formed by combining iodine atoms and organic ligands through coordination bonds, and the surface of the liposome is modified with a specific polypeptide targeting cardiac cells. The specific steps of the method for preparing the cardiac contrast agent are as follows:

[0030] Step 1, preparing an iodine-based complex, coordinating the lone pair of electrons in the organic ligand with the empty orbital of the iodine atom, wherein the organic ligand contains nitrogen, oxygen and sulfur atoms, adding iodine and the organic ligand into a sealed stirring tank for mixing, adding an inert gas into the sealed stirring tank during the reaction, stirring the reaction at 45° C., and adding a pH adjuster to adjust the pH value of the mixed solution to obtain an iodine-based complex mixed solution;

[0031] Step 2, preparing an iodine-based complex encapsulated in nano-liposomes, dissolving a lipid material in an organic solution to prepare a lipid solution, dropping the iodine-based complex mixed solution into the lipid solution, stirring until the iodine-based complex mixed solution is completely dissolved, preparing a mixed base material, and then transferring the mixed base material to a rotary evaporator, removing the organic solvent under vacuum conditions to form a uniform lipid film, adding a stabilizer thereto, hydrating for 1 hour, and then ultrasonically treating the film to prepare a crude iodine-based complex suspension encapsulated in liposomes, filtering the suspension through a nano-scale filter, and preparing an iodine-based complex encapsulated in nano-liposomes with uniform particle size;

[0032] Step 3: modifying the surface of the nano-liposome with a specific peptide targeting cardiac cells, introducing active groups on the surface of the nano-liposome using a chemical coupling method, and connecting the specific peptide to the active group using a chemical reaction to obtain an iodine-based complex encapsulated by the nano-liposome modified with the specific peptide;

[0033] Step 4: Performing quality inspection on the iodine-based complex encapsulated by the nano-liposome modified with the specific peptide, including its physical properties, chemical properties and stability under different states, and performing biocompatibility testing and imaging effect evaluation;

[0034] Step 5: sterilize the iodine-based complex encapsulated by the nano-liposome modified with the specific polypeptide that has passed the test, and put it into a sterile glass syringe that meets medical standards and store it at 2°C-8°C.

[0035] In one embodiment of the present invention: in step 1, the organic ligand is a nitrogen-containing heterocyclic compound, and during the stirring of iodine and the organic ligand, a pH adjuster is added according to the pH value of the reaction system to adjust the pH value of the finally obtained iodine-based complex mixed solution to between 7.35 and 7.45.

[0036] In one embodiment of the present invention: the pH values ​​of all materials prepared in step 1 to step 5 need to be controlled between 7.25-7.45.

[0037] In one embodiment of the present invention: in step 2, the stabilizer is ethylenediaminetetraacetic acid, and the main components of the lipid solution are phospholipids and cholesterol, and the mass ratio thereof is 1:1.

[0038] In one embodiment of the present invention: in step 2, the ultrasonic frequency is 20kHz-80kHz, the ultrasonic time is 15min-20min, and the pore size of the nano-filter is 200nm-300nm.

[0039] In one embodiment of the present invention: in step three, before modifying the surface of the nano-liposome with a specific polypeptide targeting cardiac cells, the active groups on the surface of the nano-liposome need to be activated, and the activator is 1-ethyl-3-carbodiimide.

[0040] In one embodiment of the present invention: in step three, the specific operation method is as follows:

[0041] The prepared nano-scale liposomes are subjected to ultrafiltration to remove impurities, and the pH value thereof is adjusted to between 7.35 and 7.45. The liposomes are treated with a chemical reagent, dithiothreitol, to expose thiol groups on the surface of the liposomes for reaction, and the specific polypeptide is chemically modified to introduce a maleimide group at one end thereof. After the modification, the polypeptide solution is mixed with the pretreated liposome solution, and after slow stirring, the mixture is placed in an oxygen-free, light-proof environment at a temperature of 4°C to 10°C for natural reaction for 2h to 4h. After the reaction is completed, glutathione is added to terminate the reaction, and the product is purified by gel filtration chromatography to obtain an iodine-based complex encapsulated by nano-scale liposomes modified with the specific polypeptide.

[0042] In one embodiment of the present invention: in step four, the physical properties include particle size distribution, potential measurement and morphological observation, the chemical properties include iodine content measurement and organic ligand binding ratio, the stability under different states includes thermal stability, acid-base stability and long-term storage stability, the biocompatibility includes cytotoxicity test and in vivo metabolic distribution, and the imaging effect evaluation includes in vitro simulation of the cardiac environment.

[0043] A cardiac contrast agent is prepared by encapsulating an iodine-based complex with nano-liposomes and then modifying the surface with specific polypeptides.

[0044] In one embodiment of the present invention, the specific polypeptide is a short peptide sequence that can specifically bind to a receptor on the surface of a myocardial cell membrane.

[0045] In one embodiment of the present invention: the solvent is 0.9% physiological saline.

[0046] Embodiment 1

[0047] The lone pair of electrons in the nitrogen-containing heterocyclic compound is coordinated with the empty orbital of the iodine atom, and the iodine and the nitrogen-containing heterocyclic compound are added into a sealed stirring tank for mixing. During the reaction, N2 is added into the sealed stirring tank, and the reaction is stirred at a temperature of 45°C, and a pH adjuster is added to adjust the pH value of the mixed solution to 7.35 to prepare an iodine-based complex mixed solution, and a lipid material is dissolved in 0.9% physiological saline to prepare a lipid solution, wherein the main components of the lipid solution are phospholipids and cholesterol in a mass ratio of 1:1, and the iodine-based complex mixed solution is added dropwise to the lipid solution and stirred until The iodine-based complex mixed solution is completely dissolved to obtain a mixed base material, which is then transferred to a rotary evaporator, and the physiological saline in the mixed base material is removed under vacuum conditions at a temperature of 40° C. to form a uniform lipid film, and ethylenediaminetetraacetic acid is added thereto. After hydration for 1 hour, the mixed base material is subjected to ultrasonic treatment for 20 minutes at an ultrasonic frequency of 20 kHz-80 kHz to obtain a crude liposome-encapsulated iodine-based complex suspension, and the suspension is filtered through a nano-filter with a pore size of 200 nm to obtain a nano-liposome-encapsulated iodine-based complex with uniform particle size;

[0048] The prepared nano-scale liposomes are subjected to ultrafiltration to remove impurities, and then the active groups on the surface are activated. The activator is 1-ethyl-3-carbodiimide, and its pH value is adjusted to 7.35. The liposomes are then treated with a chemical reagent, dithiothreitol, to expose the thiol groups on the surface for reaction, and the specific polypeptide is chemically modified to introduce a maleimide group at one end. After the modification, the polypeptide solution is mixed with the pre-treated liposome solution, and after slow stirring, it is placed in an oxygen-free, light-proof environment at a temperature of 4°C-10°C for natural reaction for 4 hours. After the reaction is completed, glutathione is added to terminate the reaction, and the product is purified by gel filtration chromatography to obtain an iodine-based complex encapsulated by nano-scale liposomes modified with specific polypeptides.

[0049] Embodiment 2

[0050] The lone pair of electrons in the nitrogen-containing heterocyclic compound is coordinated with the empty orbital of the iodine atom, and the iodine and the nitrogen-containing heterocyclic compound are added into a sealed stirring tank for mixing. During the reaction, N2 is added into the sealed stirring tank, and the reaction is stirred at a temperature of 45°C, and a pH adjuster is added to adjust the pH value of the mixed solution to 7.35 to prepare an iodine-based complex mixed solution, and a lipid material is dissolved in 0.9% physiological saline to prepare a lipid solution, wherein the main components of the lipid solution are phospholipids and cholesterol in a mass ratio of 1:1, and the iodine-based complex mixed solution is added dropwise to the lipid solution and stirred until The iodine-based complex mixed solution is completely dissolved to obtain a mixed base material, which is then transferred to a rotary evaporator, and the physiological saline in the mixed base material is removed under vacuum conditions at a temperature of 40° C. to form a uniform lipid film, and ethylenediaminetetraacetic acid is added thereto. After hydration for 1 hour, the mixed base material is subjected to ultrasonic treatment for 20 minutes at an ultrasonic frequency of 20kHz-80kHz to obtain a crude liposome-encapsulated iodine-based complex suspension, and the suspension is filtered through a nano-filter with a pore size of 250nm to obtain a nano-liposome-encapsulated iodine-based complex with uniform particle size;

[0051] The prepared nano-scale liposomes are subjected to ultrafiltration to remove impurities, and then the active groups on the surface are activated. The activator is 1-ethyl-3-carbodiimide, and its pH value is adjusted to 7.35. The liposomes are then treated with a chemical reagent, dithiothreitol, to expose the thiol groups on the surface for reaction, and the specific polypeptide is chemically modified to introduce a maleimide group at one end. After the modification, the polypeptide solution is mixed with the pre-treated liposome solution, and after slow stirring, it is placed in an oxygen-free, light-proof environment at a temperature of 4°C-10°C for natural reaction for 4 hours. After the reaction is completed, glutathione is added to terminate the reaction, and the product is purified by gel filtration chromatography to obtain an iodine-based complex encapsulated by nano-scale liposomes modified with specific polypeptides.

[0052] Embodiment 3

[0053] The lone pair of electrons in the nitrogen-containing heterocyclic compound is coordinated with the empty orbital of the iodine atom, and the iodine and the nitrogen-containing heterocyclic compound are added into a sealed stirring tank for mixing. During the reaction, N2 is added into the sealed stirring tank, and the reaction is stirred at a temperature of 45°C, and a pH adjuster is added to adjust the pH value of the mixed solution to 7.35 to prepare an iodine-based complex mixed solution, and a lipid material is dissolved in 0.9% physiological saline to prepare a lipid solution, wherein the main components of the lipid solution are phospholipids and cholesterol in a mass ratio of 1:1, and the iodine-based complex mixed solution is added dropwise to the lipid solution and stirred until The iodine-based complex mixed solution is completely dissolved to obtain a mixed base material, which is then transferred to a rotary evaporator, and the physiological saline in the mixed base material is removed under vacuum conditions at a temperature of 40° C. to form a uniform lipid film, and ethylenediaminetetraacetic acid is added thereto. After hydration for 1 hour, the mixed base material is subjected to ultrasonic treatment for 20 minutes at an ultrasonic frequency of 20 kHz-80 kHz to obtain a crude liposome-encapsulated iodine-based complex suspension, and the suspension is filtered through a nano-filter with a pore size of 300 nm to obtain a nano-liposome-encapsulated iodine-based complex with uniform particle size;

[0054] The prepared nano-scale liposomes are subjected to ultrafiltration to remove impurities, and then the active groups on the surface are activated. The activator is 1-ethyl-3-carbodiimide, and its pH value is adjusted to 7.35. The liposomes are then treated with a chemical reagent, dithiothreitol, to expose the thiol groups on the surface for reaction, and the specific polypeptide is chemically modified to introduce a maleimide group at one end. After the modification, the polypeptide solution is mixed with the pre-treated liposome solution, and after slow stirring, it is placed in an oxygen-free, light-proof environment at a temperature of 4°C-10°C for natural reaction for 4 hours. After the reaction is completed, glutathione is added to terminate the reaction, and the product is purified by gel filtration chromatography to obtain an iodine-based complex encapsulated by nano-scale liposomes modified with specific polypeptides.

[0055] Particle size distribution: Dynamic scattering (DLS) was used to measure the particle size and distribution of liposomes to ensure that they were at the nanoscale and uniformly distributed.

[0056] Potential measurement: The surface potential of the composite was measured using a zeta potential meter;

[0057] Morphological observation: The morphology and structure of the composite were observed and recorded using a transmission electron microscope (TEM);

[0058] Iodine content determination: The iodine content in the complex is determined using the iodine titration method to ensure the contrast effect;

[0059] Organic ligand binding ratio: The binding ratio of organic ligand to iodine atom was measured by infrared spectrometer;

[0060] Thermal stability: The composite was placed in different temperature environments for 45 minutes to detect changes in its physical and chemical properties;

[0061] Acid-base stability: The stability of the complex was tested in solutions with different pH values;

[0062] Long-term storage stability: monitor the changes in the properties of the compound over a period of time and evaluate its storage conditions and shelf life;

[0063] Cytotoxicity assay:

[0064] Materials: cardiomyocyte cell lines, cell culture medium, MTT reagent, etc.

[0065] Instruments: cell culture incubator, microplate reader;

[0066] Methods: The complex was co-cultured with cardiomyocytes, and the cell survival rate was detected by MTT assay to evaluate its cytotoxic effect;

[0067] Metabolism and distribution in the body:

[0068] Materials: Experimental animals: mice, radiolabeled complexes;

[0069] Instruments: Gamma counter;

[0070] Methods: Animals were injected with labeled complexes, and blood and tissue samples were collected at different time points to detect the content and distribution of the complexes;

[0071] In vitro simulated cardiac environment:

[0072] Materials: Fluid devices that simulate the heart, X-ray imaging equipment, and magnetic resonance imaging machines;

[0073] Methods: The complex was placed in a simulation device and the contrast effect was observed using imaging equipment;

[0074] Image clarity: The clarity of blood vessels, cardiac structures, etc. was evaluated by observing the generated cardiac angiography images, using a subjective scoring standard with a 1-5 point scale from blurry to very clear.

[0075] As attached Figure 2 -Attached Figure 3As shown, the in vivo metabolism of the iodine-based complex encapsulated by the nano-liposome modified with the specific polypeptide prepared by the present invention is mainly affected by the particle size. The larger the particle size of the iodine-based complex encapsulated by the nano-liposome, the smaller the in vivo metabolism in the same time. When the particle size is between 200nm-300nm, it will not affect the imaging effect of the iodine-based complex encapsulated by the nano-liposome. When the particle size is 300nm, the in vivo metabolism amount is still normal. The unit of the in vivo metabolism amount is ug / mL, and the amount of this unit is the amount metabolized every 10min.

[0076] Attached Figure 1 With attached Figure 2 The data in Examples 1 to 3 correspond to each other.

[0077] The embodiments of the present invention are described in detail above with reference to the accompanying drawings, but the present invention is not limited to the described embodiments. For those skilled in the art, various changes, modifications, substitutions and variations of these embodiments are made without departing from the principles and spirit of the present invention, and still fall within the scope of protection of the present invention.

[0078] In the description of the specification, the description with reference to the terms "one embodiment", "example", "specific example", etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner.

[0079] The above contents are merely examples and explanations of the present invention. Various modifications or additions to the specific embodiments described or replacements in similar ways by technicians in the technical field shall fall within the protection scope of the present invention as long as they do not deviate from the invention or exceed the scope defined by the claims.

[0080] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

Claims

1. A method for preparing a cardiac contrast agent, characterized in that: The basic materials used in the preparation of the cardiac contrast agent are an iodine-based complex, a stabilizer, a pH regulator and an organic solution. The iodine-based complex is a complex encapsulated by nano-liposomes. The iodine-based complex is formed by combining iodine atoms and organic ligands through coordination bonds, and the surface of the liposome is modified with a specific polypeptide targeting cardiac cells. The specific steps of the preparation method of the cardiac contrast agent are as follows: Step 1, preparing an iodine-based complex, coordinating the lone pair of electrons in the organic ligand with the empty orbital of the iodine atom, wherein the organic ligand contains nitrogen, oxygen and sulfur atoms, adding iodine and the organic ligand into a sealed stirring tank for mixing, adding an inert gas into the sealed stirring tank during the reaction, stirring the reaction at 45° C., and adding a pH adjuster to adjust the pH value of the mixed solution to obtain an iodine-based complex mixed solution; Step 2, preparing an iodine-based complex encapsulated in nano-liposomes, dissolving a lipid material in an organic solution to prepare a lipid solution, dropping the iodine-based complex mixed solution into the lipid solution, stirring until the iodine-based complex mixed solution is completely dissolved, preparing a mixed base material, and then transferring the mixed base material to a rotary evaporator, removing the organic solvent under vacuum conditions to form a uniform lipid film, adding a stabilizer thereto, hydrating for 1 hour, and then ultrasonically treating the film to prepare a crude iodine-based complex suspension encapsulated in liposomes, filtering the suspension through a nano-scale filter, and preparing an iodine-based complex encapsulated in nano-liposomes with uniform particle size; Step 3: modifying the surface of the nano-liposome with a specific peptide targeting cardiac cells, introducing active groups on the surface of the nano-liposome using a chemical coupling method, and connecting the specific peptide to the active group using a chemical reaction to obtain an iodine-based complex encapsulated by the nano-liposome modified with the specific peptide; Step 4: Performing quality inspection on the iodine-based complex encapsulated by the nano-liposome modified with the specific peptide, including its physical properties, chemical properties and stability under different states, and performing biocompatibility testing and imaging effect evaluation; Step 5: sterilize the iodine-based complex encapsulated by the nano-liposome modified with the specific polypeptide that has passed the test, and put it into a sterile glass syringe that meets medical standards and store it at 2°C-8°C.

2. The method for preparing a cardiac contrast agent according to claim 1, characterized in that: In the step 1, the organic ligand is a nitrogen-containing heterocyclic compound. During the stirring of iodine and the organic ligand, a pH adjuster is added according to the pH value of the reaction system to adjust the pH value of the finally obtained iodine-based complex mixed solution to between 7.35 and 7.

45.

3. The method for preparing a cardiac contrast agent according to claim 1, characterized in that: The pH values ​​of all materials prepared in step 1 to step 5 need to be controlled between 7.25 and 7.

45.

4. The method for preparing a cardiac contrast agent according to claim 1, characterized in that: In the step 2, the stabilizer is ethylenediaminetetraacetic acid, and the main components of the lipid solution are phospholipids and cholesterol, and the mass ratio thereof is 1:

1.

5. The method for preparing a cardiac contrast agent according to claim 1, characterized in that: In the step 2, the ultrasonic frequency is 20kHz-80kHz, the ultrasonic time is 15min-20min, and the pore size of the nano-filter is 200nm-300nm.

6. The method for preparing a cardiac contrast agent according to claim 1, characterized in that: In the step 3, before modifying the surface of the nano-sized liposome with the specific polypeptide targeting cardiac cells, the active groups on the surface of the nano-sized liposome need to be activated, and the activating agent is 1-ethyl-3-carbodiimide.

7. The method for preparing a cardiac contrast agent according to claim 1, characterized in that: In step three, the specific operation method is as follows: The prepared nano-scale liposomes are subjected to ultrafiltration to remove impurities, and the pH value thereof is adjusted to between 7.35 and 7.

45. The liposomes are treated with a chemical reagent, dithiothreitol, to expose thiol groups on the surface of the liposomes for reaction, and the specific polypeptide is chemically modified to introduce a maleimide group at one end thereof. After the modification, the polypeptide solution is mixed with the pretreated liposome solution, and after slow stirring, the mixture is placed in an oxygen-free, light-proof environment at a temperature of 4°C to 10°C for natural reaction for 2h to 4h. After the reaction is completed, glutathione is added to terminate the reaction, and the product is purified by gel filtration chromatography to obtain an iodine-based complex encapsulated by nano-scale liposomes modified with the specific polypeptide.

8. The method for preparing a cardiac contrast agent according to claim 1, characterized in that: In step 4, the physical properties include particle size distribution, potential measurement and morphological observation, the chemical properties include iodine content measurement and organic ligand binding ratio, the stability under different states includes thermal stability, acid-base stability and long-term storage stability, the biocompatibility includes cytotoxicity test and in vivo metabolic distribution, and the imaging effect evaluation includes in vitro simulation of the cardiac environment.

9. A cardiac contrast agent suitable for the preparation method of a cardiac contrast agent according to any one of claims 1 to 8, characterized in that: The cardiac contrast agent is prepared by encapsulating an iodine-based complex with nano-liposomes and then modifying the surface with specific polypeptides.